The Rising Incidence of Younger Patients With Colorectal Cancer: Questions About Screening, Biology, and Treatment

Current Treatment Options in Oncology

Volumn 18, Issue 4, 2017, Pages

  Connell, Louise C ^a   Mota, José Mauricio ^a   Braghiroli, Maria Ignez ^a,b   Hoff, Paulo M ^a,b  

^a HOSPITAL SÍRIO LIBANÊS   (Brazil)

^b UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Chromosomal instability; CpG island methylator phenotype; Early onset colorectal cancer; Epidemiology; Hereditary syndromes; Lynch syndrome; Microsatellite instability; Nonhereditary risk factors; Screening; Sporadic early onset colorectal cancer

Indexed keywords

ADOLESCENT; ADULT; AGE; CANCER GENETICS; CANCER INCIDENCE; CANCER MORTALITY; CANCER PROGNOSIS; CANCER RESEARCH; CANCER RISK; CANCER SCREENING; CANCER SUSCEPTIBILITY; CANCER THERAPY; CAUSE OF DEATH; CLINICAL OUTCOME; COLORECTAL CANCER; DIETARY INTAKE; DISEASE ASSOCIATION; ENVIRONMENTAL FACTOR; EXERCISE; GENETIC SUSCEPTIBILITY; HEREDITY; HUMAN; LIFESTYLE; OBESITY; ONSET AGE; PATHOGENESIS; REVIEW; YOUNG ADULT; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DISEASE MANAGEMENT; EARLY CANCER DIAGNOSIS; GENETIC PREDISPOSITION; GENETICS; HEALTH SURVEY; INCIDENCE; PROCEDURES; RISK FACTOR;

ADULT; AGE FACTORS; AGE OF ONSET; COLORECTAL NEOPLASMS; COLORECTAL NEOPLASMS, HEREDITARY NONPOLYPOSIS; DISEASE MANAGEMENT; EARLY DETECTION OF CANCER; GENETIC PREDISPOSITION TO DISEASE; HUMANS; INCIDENCE; POPULATION SURVEILLANCE; RISK FACTORS; YOUNG ADULT;

EID: 85017123110     PISSN: 15272729     EISSN: 15346277     Source Type: Journal    
DOI: 10.1007/s11864-017-0463-3     Document Type: Review

References (158)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90. doi:10.3322/caac.20107.
2. Perea J, Rodríguez Y, Rueda D, Marín JC, Díaz-Tasende J, Álvaro E, et al. Early-onset colorectal cancer is an easy and effective tool to identify retrospectively Lynch syndrome. Ann Surg Oncol. 2011;18:3285–91. doi:10.1245/s10434-011-1782-4.
3. Wang M-J, Ping J, Li Y, Adell G, Arbman G, Nodin B, et al. The prognostic factors and multiple biomarkers in young patients with colorectal cancer. Sci Rep. 2015;5:10645. doi:10.1038/srep10645.
4. Kneuertz PJ, Chang GJ, Hu C-Y, Rodriguez-Bigas MA, Eng C, Vilar E, et al. Overtreatment of young adults with colon cancer: more intense treatments with unmatched survival gains. JAMA Surg. 2015;150:402–9. doi:10.1001/jamasurg.2014.3572.
5. Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–86. doi:10.1002/ijc.29210.
6. Howlader N, Noone A, Krapcho M, Miller D, K Bishop, SF Altekruse, et al. SEER cancer statistics review, 1975–2013. In: SEER web site [Internet]. 2016. Available: http://seer.cancer.gov/csr/1975_2013/.
7. Singh KE, Taylor TH, Pan C-JG, Stamos MJ, Zell JA. Colorectal cancer incidence among young adults in California. J Adolesc Young Adult Oncol. 2014;3:176–84. doi:10.1089/jayao.2014.0006.
8. Young JP, Win AK, Rosty C, Flight I, Roder D, Young GP, et al. Rising incidence of early-onset colorectal cancer in Australia over two decades: report and review. J Gastroenterol Hepatol. 2015;30:6–13. doi:10.1111/jgh.12792.
9. • Bailey CE, Hu C-Y, You YN, Bednarski BK, Rodriguez-Bigas MA, Skibber JM, et al. Increasing disparities in the age-related incidences of colon and rectal cancers in the United States, 1975-2010. JAMA Surg. 2015;150:17–22. doi:10.1001/jamasurg.2014.1756. This retrospective cohort study based on the SEER CRC registry confirms the apparent increase in the incidence of CRC in young adults and a decline in older patients
10. Bhandari A, Woodhouse M, Gupta S. Colorectal cancer is a leading cause of cancer incidence and mortality among adults younger than 50 years in the USA: a SEER-based analysis with comparison to other young-onset cancers. J Investig Med. 2016; doi:10.1136/jim-2016-000229.
11. Meyer JE, Narang T, Schnoll-Sussman FH, Pochapin MB, Christos PJ, Sherr DL. Increasing incidence of rectal cancer in patients aged younger than 40 years: an analysis of the surveillance, epidemiology, and end results database. Cancer. 2010;116:4354–9. doi:10.1002/cncr.25432.
12. Austin H, Henley SJ, King J, Richardson LC, Eheman C. Changes in colorectal cancer incidence rates in young and older adults in the United States: what does it tell us about screening. Cancer Causes Control. 2014;25:191–201. doi:10.1007/s10552-013-0321-y.
13. O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Rates of colon and rectal cancers are increasing in young adults. Am Surg. 2003;69:866–72. Available: http://www.ncbi.nlm.nih.gov/pubmed/14570365
14. Siegel RL, Jemal A, Ward EM. Increase in incidence of colorectal cancer among young men and women in the United States. Cancer Epidemiol Biomark Prev. 2009;18:1695–8. doi:10.1158/1055-9965.EPI-09-0186.
15. You YN, Xing Y, Feig BW, Chang GJ, Cormier JN. Young-onset colorectal cancer: is it time to pay attention? Arch Intern Med. 2012;172:287–9. doi:10.1001/archinternmed.2011.602.
16. Griffin PM, Liff JM, Greenberg RS, Clark WS. Adenocarcinomas of the colon and rectum in persons under 40 years old. A population-based study. Gastroenterology. 1991;100:1033–40. Available: http://www.ncbi.nlm.nih.gov/pubmed/2001800
17. Rahman R, Schmaltz C, Jackson CS, Simoes EJ, Jackson-Thompson J, Ibdah JA. Increased risk for colorectal cancer under age 50 in racial and ethnic minorities living in the United States. Cancer Med. 2015;4:1863–70. doi:10.1002/cam4.560.
18. Ashktorab H, Vilmenay K, Brim H, Laiyemo AO, Kibreab A, Nouraie M. Colorectal cancer in young African Americans: is it time to revisit guidelines and prevention? Dig Dis Sci. 2016;61:3026–30. doi:10.1007/s10620-016-4207-1.
19. • Holowatyj AN, Ruterbusch JJ, Rozek LS, Cote ML, Stoffel EM. Racial/ethnic disparities in survival among patients with young-onset colorectal cancer. J Clin Oncol. 2016;34:2148–56. doi:10.1200/JCO.2015.65.0994. Using the SEER database, the survival of patients with young-onset CRC (aged <50 years) was assessed. It was observed that the survival for CRC diagnosed at a young age is significantly worse among non-Hispanic Black patients compared to non-Hispanic White patients, even in the setting of early-stage disease
20. Dozois EJ, Boardman LA, Suwanthanma W, Limburg PJ, Cima RR, Bakken JL, et al. Young-onset colorectal cancer in patients with no known genetic predisposition: can we increase early recognition and improve outcome? Medicine (Baltimore). 2008;87:259–63. doi:10.1097/MD.0b013e3181881354.
21. O’Connell JB, Maggard MA, Liu JH, Etzioni DA, Livingston EH, Ko CY. Do young colon cancer patients have worse outcomes? World J Surg. 2004;28:558–62. Available: http://www.ncbi.nlm.nih.gov/pubmed/15366745
22. Taggarshe D, Rehil N, Sharma S, Flynn JC, Damadi A. Colorectal cancer: are the “young” being overlooked? Am J Surg. 2013;205:312–6. discussion 316 doi:10.1016/j.amjsurg.2012.10.016.
23. Teng A, Lee DY, Cai J, Patel SS, Bilchik AJ, Goldfarb MR. Patterns and outcomes of colorectal cancer in adolescents and young adults. J Surg Res. 2016;205:19–27. doi:10.1016/j.jss.2016.05.036.
24. Abdelsattar ZM, Wong SL, Regenbogen SE, Jomaa DM, Hardiman KM, Hendren S. Colorectal cancer outcomes and treatment patterns in patients too young for average-risk screening. Cancer. 2016;122:929–34. doi:10.1002/cncr.29716.
25. Chen FW, Sundaram V, Chew TA, Ladabaum U. Advanced stage colorectal cancer in persons younger than 50 years not associated with longer duration of symptoms or time to diagnosis. Clin Gastroenterol Hepatol. 2016; doi:10.1016/j.cgh.2016.10.038.
26. Lisa A, Boardman EB. Genetics of young onset colorectal cancer. J Bone Marrow Res. 2014;3 doi:10.4172/2161-1041.1000124.
27. Aarnio M. Clinicopathological features and management of cancers in Lynch syndrome. Patholog Res Int. 2012;2012:350309. doi:10.1155/2012/350309.
28. Peltomäki P. Role of DNA mismatch repair defects in the pathogenesis of human cancer. J Clin Oncol. 2003;21:1174–9. doi:10.1200/JCO.2003.04.060.
29. Stoffel E, Mukherjee B, Raymond VM, Tayob N, Kastrinos F, Sparr J, et al. Calculation of risk of colorectal and endometrial cancer among patients with Lynch syndrome. Gastroenterology. 2009;137:1621–7. doi:10.1053/j.gastro.2009.07.039.
30. Lynch HT, de la Chapelle A. Hereditary colorectal cancer. N Engl J Med. 2003;348:919–32. doi:10.1056/NEJMra012242.
31. Watson P, Lin KM, Rodriguez-Bigas MA, Smyrk T, Lemon S, Shashidharan M, et al. Colorectal carcinoma survival among hereditary nonpolyposis colorectal carcinoma family members. Cancer. 1998;83:259–66. Available: http://www.ncbi.nlm.nih.gov/pubmed/9669808
32. Senter L, Clendenning M, Sotamaa K, Hampel H, Green J, Potter JD, et al. The clinical phenotype of Lynch syndrome due to germ-line PMS2 mutations. Gastroenterology. 2008;135:419–28. doi:10.1053/j.gastro.2008.04.026.
33. Bonadona V, Bonaïti B, Olschwang S, Grandjouan S, Huiart L, Longy M, et al. Cancer risks associated with germline mutations in MLH1, MSH2, and MSH6 genes in Lynch syndrome. JAMA. 2011;305:2304–10. doi:10.1001/jama.2011.743.
34. Wennstrom J, Pierce ER, McKusick VA. Hereditary benign and malignant lesions of the large bowel. Cancer. 1974;34:850–7. Available: http://www.ncbi.nlm.nih.gov/pubmed/4604530
35. Kastrinos F, Syngal S. Inherited colorectal cancer syndromes. Cancer J. 2011;17:405–15. doi:10.1097/PPO.0b013e318237e408.
36. Galiatsatos P, Foulkes WD. Familial adenomatous polyposis. Am J Gastroenterol. 2006;101:385–98. doi:10.1111/j.1572-0241.2006.00375.x.
37. Cruz-Correa M, Giardiello FM. Familial adenomatous polyposis. Gastrointest Endosc. 2003;58:885–94. Available: http://www.ncbi.nlm.nih.gov/pubmed/14652558
38. Patel SG, Ahnen DJ. Familial colon cancer syndromes: an update of a rapidly evolving field. Curr Gastroenterol Rep. 2012;14:428–38. doi:10.1007/s11894-012-0280-6.
39. Jasperson KW, Tuohy TM, Neklason DW, Burt RW. Hereditary and familial colon cancer. Gastroenterology. 2010;138:2044–58. doi:10.1053/j.gastro.2010.01.054.
40. Half E, Bercovich D, Rozen P. Familial adenomatous polyposis. Orphanet J Rare Dis. 2009;4:22. doi:10.1186/1750-1172-4-22.
41. Lubbe SJ, Di Bernardo MC, Chandler IP, Houlston RS. Clinical implications of the colorectal cancer risk associated with MUTYH mutation. J Clin Oncol. 2009;27:3975–80. doi:10.1200/JCO.2008.21.6853.
42. Sampson JR, Dolwani S, Jones S, Eccles D, Ellis A, Evans DG, et al. Autosomal recessive colorectal adenomatous polyposis due to inherited mutations of MYH. Lancet (London, England). 2003;362:39–41. doi:10.1016/S0140-6736(03)13805-6.
43. Jenkins MA, Croitoru ME, Monga N, Cleary SP, Cotterchio M, Hopper JL, et al. Risk of colorectal cancer in monoallelic and biallelic carriers of MYH mutations: a population-based case-family study. Cancer Epidemiol Biomark Prev. 2006;15:312–4. doi:10.1158/1055-9965.EPI-05-0793.
44. van Lier MGF, Wagner A, Mathus-Vliegen EMH, Kuipers EJ, Steyerberg EW, van Leerdam ME. High cancer risk in Peutz–Jeghers syndrome: a systematic review and surveillance recommendations. Am J Gastroenterol. 2010;105:1258–64. doi:10.1038/ajg.2009.725.
45. Jass JR, Williams CB, Bussey HJ, Morson BC. Juvenile polyposis—a precancerous condition. Histopathology. 1988;13:619–30. Available: http://www.ncbi.nlm.nih.gov/pubmed/2853131
46. Lachlan KL. Cowden syndrome and the PTEN hamartoma tumor syndrome: how to define rare genetic syndromes. J Natl Cancer Inst. 2013;105:1595–7. doi:10.1093/jnci/djt290.
47. Win AK, Walters RJ, Buchanan DD, Jenkins MA, Sweet K, Frankel WL, et al. Cancer risks for relatives of patients with serrated polyposis. Am J Gastroenterol. 2012;107:770–8. doi:10.1038/ajg.2012.52.
48. Flegal KM, Carroll MD, Ogden CL, Johnson CL. Prevalence and trends in obesity among US adults, 1999-2000. JAMA. 2002;288:1723–7. Available: http://www.ncbi.nlm.nih.gov/pubmed/12365955
49. Centers for Disease Control and Prevention (CDC). Trends in leisure-time physical inactivity by age, sex, and race/ethnicity—United States, 1994-2004. MMWR Morb Mortal Wkly Rep. 2005;54:991–4. Available: http://www.ncbi.nlm.nih.gov/pubmed/16208312
50. Pan SY, DesMeules M. Energy intake, physical activity, energy balance, and cancer: epidemiologic evidence. Methods Mol Biol. 2009;472:191–215. doi:10.1007/978-1-60327-492-0_8.
51. Slattery ML, Sorenson AW, Mahoney AW, French TK, Kritchevsky D, Street JC. Diet and colon cancer: assessment of risk by fiber type and food source. JNCI J Natl Cancer Inst. 1988;80:1474–80. doi:10.1093/jnci/80.18.1474.
52. Crosara Teixeira M, Braghiroli MI, Sabbaga J, Hoff PM. Primary prevention of colorectal cancer: myth or reality? World J Gastroenterol. 2014;20:15060–9. doi:10.3748/wjg.v20.i41.15060.
53. Lin J. Dietary fat and fatty acids and risk of colorectal cancer in women. Am J Epidemiol. 2004;160:1011–22. doi:10.1093/aje/kwh319.
54. Karahalios A, English DR, Simpson JA. Weight change and risk of colorectal cancer: a systematic review and meta-analysis. Am J Epidemiol. 2015;181:832–45. doi:10.1093/aje/kwu357.
55. Wolin KY, Yan Y, Colditz GA, Lee I-M. Physical activity and colon cancer prevention: a meta-analysis. Br J Cancer. 2009;100:611–6. doi:10.1038/sj.bjc.6604917.
56. Yuhara H, Steinmaus C, Cohen SE, Corley DA, Tei Y, Buffler PA. Is diabetes mellitus an independent risk factor for colon cancer and rectal cancer? Am J Gastroenterol. 2011;106:1911–21. doi:10.1038/ajg.2011.301.
57. Botteri E, Iodice S, Bagnardi V, Raimondi S, Lowenfels AB, Maisonneuve P. Smoking and colorectal cancer: a meta-analysis. JAMA. 2008;300:2765–78. doi:10.1001/jama.2008.839.
58. Wallace K, Grau MV, Ahnen D, Snover DC, Robertson DJ, Mahnke D, et al. The association of lifestyle and dietary factors with the risk for serrated polyps of the colorectum. Cancer Epidemiol Biomark Prev. 2009;18:2310–7. doi:10.1158/1055-9965.EPI-09-0211.
59. Botteri E, Iodice S, Raimondi S, Maisonneuve P, Lowenfels AB. Cigarette smoking and adenomatous polyps: a meta-analysis. Gastroenterology. 2008;134:388–95. doi:10.1053/j.gastro.2007.11.007.
60. Fedirko V, Tramacere I, Bagnardi V, Rota M, Scotti L, Islami F, et al. Alcohol drinking and colorectal cancer risk: an overall and dose-response meta-analysis of published studies. Ann Oncol Off J Eur Soc Med Oncol. 2011;22:1958–72. doi:10.1093/annonc/mdq653.
61. Cho E, Smith-Warner SA, Ritz J, van den Brandt PA, Colditz GA, Folsom AR, et al. Alcohol intake and colorectal cancer: a pooled analysis of 8 cohort studies. Ann Intern Med. 2004;140:603–13. Available: http://www.ncbi.nlm.nih.gov/pubmed/15096331
62. Mizoue T, Inoue M, Wakai K, Nagata C, Shimazu T, Tsuji I, et al. Alcohol drinking and colorectal cancer in Japanese: a pooled analysis of results from five cohort studies. Am J Epidemiol. 2008;167:1397–406. doi:10.1093/aje/kwn073.
63. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin. 2010;60:277–300. doi:10.3322/caac.20073.
64. Lynch KL, Ahnen DJ, Byers T, Weiss DG, Lieberman DA. First-degree relatives of patients with advanced colorectal adenomas have an increased prevalence of colorectal cancer. Clin Gastroenterol Hepatol. 2003;1:96–102. doi:10.1053/cgh.2003.50018.
65. Lieberman DA, Prindiville S, Weiss DG, Willett W, VA Cooperative Study Group 380. Risk factors for advanced colonic neoplasia and hyperplastic polyps in asymptomatic individuals. JAMA. 2003;290:2959–67. doi:10.1001/jama.290.22.2959.
66. Fuchs CS, Giovannucci EL, Colditz GA, Hunter DJ, Speizer FE, Willett WC. A prospective study of family history and the risk of colorectal cancer. N Engl J Med. 1994;331:1669–74. doi:10.1056/NEJM199412223312501.
67. Butterworth AS, Higgins JPT, Pharoah P. Relative and absolute risk of colorectal cancer for individuals with a family history: a meta-analysis. Eur J Cancer. 2006;42:216–27. doi:10.1016/j.ejca.2005.09.023.
68. Lieberman DA, Rex DK, Winawer SJ, Giardiello FM, Johnson DA, Levin TR, et al. Guidelines for colonoscopy surveillance after screening and polypectomy: a consensus update by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2012;143:844–57. doi:10.1053/j.gastro.2012.06.001.
69. Qaseem A, Denberg TD, Hopkins RH, Humphrey LL, Levine J, Sweet DE, et al. Screening for colorectal cancer: a guidance statement from the American College of Physicians. Ann Intern Med. 2012;156:378–86. doi:10.7326/0003-4819-156-5-201203060-00010.
70. Gupta AK, Samadder J, Elliott E, Sethi S, Schoenfeld P. Prevalence of any size adenomas and advanced adenomas in 40- to 49-year-old individuals undergoing screening colonoscopy because of a family history of colorectal carcinoma in a first-degree relative. Gastrointest Endosc. 2011;74:110–8. doi:10.1016/j.gie.2011.02.010.
71. Garcia GH, Riechelmann RP, Hoff PM. Adherence to colonoscopy recommendations for first-degree relatives of young patients diagnosed with colorectal cancer. Clinics (Sao Paulo). 2015;70:696–9. doi:10.6061/clinics/2015(10)07.
72. Akhtar S, Sinha S, McKenzie S, Sagar PM, Finan PJ, Burke D. Awareness of risk factors amongst first degree relative patients with colorectal cancer. Color Dis. 2008;10:887–90. doi:10.1111/j.1463-1318.2008.01502.x.
73. Hogan NM, Hanley M, Hogan AM, Sheehan M, McAnena OJ, Regan MP, et al. Awareness and uptake of family screening in patients diagnosed with colorectal cancer at a young age. Gastroenterol Res Pract. 2015;2015:194931. doi:10.1155/2015/194931.
74. Austin GL, Goldstein JI, Peters SL, Ahnen DJ. Are colorectal cancer screening recommendations for first-degree relatives of patients with adenomas too aggressive? Clin Gastroenterol Hepatol. 2011;9:308–13. doi:10.1016/j.cgh.2011.01.004.
75. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Dis Colon Rectum. 2014;57:1025–48. doi:10.1097/DCR.000000000000000.
76. Stoffel EM, Mangu PB, Gruber SB, Hamilton SR, Kalady MF, Lau MWY, et al. Hereditary colorectal cancer syndromes: American Society of Clinical Oncology Clinical Practice Guideline endorsement of the familial risk-colorectal cancer: European Society for Medical Oncology Clinical Practice Guidelines. J Clin Oncol. 2015;33:209–17. doi:10.1200/JCO.2014.58.1322.
77. Balmaña J, Balaguer F, Cervantes A, Arnold D, ESMO Guidelines Working Group. Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines. Ann Oncol Off J Eur Soc Med Oncol. 2013;24(Suppl 6):vi73–80. doi:10.1093/annonc/mdt209.
78. Barrow P, Khan M, Lalloo F, Evans DG, Hill J. Systematic review of the impact of registration and screening on colorectal cancer incidence and mortality in familial adenomatous polyposis and Lynch syndrome. Br J Surg. 2013;100:1719–31. doi:10.1002/bjs.9316.
79. Järvinen HJ, Aarnio M, Mustonen H, Aktan-Collan K, Aaltonen LA, Peltomäki P, et al. Controlled 15-year trial on screening for colorectal cancer in families with hereditary nonpolyposis colorectal cancer. Gastroenterology. 2000;118:829–34. Available: http://www.ncbi.nlm.nih.gov/pubmed/10784581
80. Syngal S, Weeks JC, Schrag D, Garber JE, Kuntz KM. Benefits of colonoscopic surveillance and prophylactic colectomy in patients with hereditary nonpolyposis colorectal cancer mutations. Ann Intern Med. 1998;129:787–96. Available: http://www.ncbi.nlm.nih.gov/pubmed/9841584
81. Giardiello FM, Allen JI, Axilbund JE, Boland CR, Burke CA, Burt RW, et al. Guidelines on genetic evaluation and management of Lynch syndrome: a consensus statement by the US Multi-Society Task Force on Colorectal Cancer. Gastroenterology. 2014;147:502–26. doi:10.1053/j.gastro.2014.04.001.
82. Vasen HFA, Möslein G, Alonso A, Aretz S, Bernstein I, Bertario L, et al. Guidelines for the clinical management of familial adenomatous polyposis (FAP). Gut. 2008;57:704–13. doi:10.1136/gut.2007.136127.
83. Syngal S, Brand RE, Church JM, Giardiello FM, Hampel HL, Burt RW, et al. ACG clinical guideline: genetic testing and management of hereditary gastrointestinal cancer syndromes. Am J Gastroenterol. 2015;110:223–62. quiz 263 doi:10.1038/ajg.2014.435.
84. Provenzale D, Gupta S, Ahnen DJ, Bray T, Cannon JA, Cooper G, et al. Genetic/familial high-risk assessment: colorectal version 1.2016, NCCN clinical practice guidelines in oncology. J Natl Compr Cancer Netw. 2016;14:1010–30. Available: http://www.ncbi.nlm.nih.gov/pubmed/27496117
85. Sengupta N, Yee E, Feuerstein JD. Colorectal cancer screening in inflammatory bowel disease. Dig Dis Sci. 2016;61:980–9. doi:10.1007/s10620-015-3979-z.
86. Söderlund S, Brandt L, Lapidus A, Karlén P, Broström O, Löfberg R, et al. Decreasing time-trends of colorectal cancer in a large cohort of patients with inflammatory bowel disease. Gastroenterology. 2009;136:1561–7. Available: http://www.ncbi.nlm.nih.gov/pubmed/19422077
87. Beaugerie L, Itzkowitz SH. Cancers complicating inflammatory bowel disease. N Engl J Med. 2015;372:1441–52. doi:10.1056/NEJMra1403718.
88. Lopez A, Collet-Fenetrier B, Belle A, Peyrin-Biroulet L. Patients’ knowledge and fear of colorectal cancer risk in inflammatory bowel disease. J Dig Dis. 2016;17:383–91. doi:10.1111/1751-2980.12356.
89. Kornbluth A, Sachar DB, Practice Parameters Committee of the American College of Gastroenterology. Ulcerative colitis practice guidelines in adults: American College of Gastroenterology, Practice Parameters Committee. Am J Gastroenterol. 2010;105:501–23. quiz 524 doi:10.1038/ajg.2009.727.
90. American Society for Gastrointestinal Endoscopy Standards of Practice Committee, Shergill AK, Lightdale JR, Bruining DH, Acosta RD, Chandrasekhara V, et al. The role of endoscopy in inflammatory bowel disease. Gastrointest Endosc. 2015;81:1101–21.e1-13. doi:10.1016/j.gie.2014.10.030.
91. Cairns SR, Scholefield JH, Steele RJ, Dunlop MG, Thomas HJW, Evans GD, et al. Guidelines for colorectal cancer screening and surveillance in moderate and high risk groups (update from 2002). Gut. 2010;59:666–89. doi:10.1136/gut.2009.179804.
92. Soetikno R, Subramanian V, Kaltenbach T, Rouse RV, Sanduleanu S, Suzuki N, et al. The detection of nonpolypoid (flat and depressed) colorectal neoplasms in patients with inflammatory bowel disease. Gastroenterology. 2013;144:1349–52. 1352–6 doi:10.1053/j.gastro.2013.04.008.
93. Mooiweer E, van der Meulen-de Jong AE, Ponsioen CY, Fidder HH, Siersema PD, Dekker E, et al. Chromoendoscopy for surveillance in inflammatory bowel disease does not increase neoplasia detection compared with conventional colonoscopy with random biopsies: results from a large retrospective study. Am J Gastroenterol. 2015;110:1014–21. doi:10.1038/ajg.2015.63.
94. Bopanna S, Roy M, Das P, Dattagupta S, Sreenivas V, Mouli VP, et al. Role of random biopsies in surveillance of dysplasia in ulcerative colitis patients with high risk of colorectal cancer. Intest Res. 2016;14:264–9. doi:10.5217/ir.2016.14.3.264.
95. Edwards BK, Ward E, Kohler BA, Eheman C, Zauber AG, Anderson RN, et al. Annual report to the nation on the status of cancer, 1975-2006, featuring colorectal cancer trends and impact of interventions (risk factors, screening, and treatment) to reduce future rates. Cancer. 2010;116:544–73. doi:10.1002/cncr.24760.
96. US Preventive Services Task Force, Bibbins-Domingo K, Grossman DC, Curry SJ, Davidson KW, Epling JW, et al. Screening for colorectal cancer: US Preventive Services Task Force recommendation statement. JAMA. 2016;315:2564–75. doi:10.1001/jama.2016.5989.
97. Ahnen DJ, Wade SW, Jones WF, Sifri R, Mendoza Silveiras J, Greenamyer J, et al. The increasing incidence of young-onset colorectal cancer: a call to action. Mayo Clin Proc. 2014;89:216–24. doi:10.1016/j.mayocp.2013.09.006.
98. Williams R, White P, Nieto J, Vieira D, Francois F, Hamilton F. Colorectal cancer in African Americans: an update. Clin Transl Gastroenterol. 2016;7:e185. doi:10.1038/ctg.2016.36.
99. Rex DK, Johnson DA, Anderson JC, Schoenfeld PS, Burke CA, Inadomi JM, et al. American College of Gastroenterology guidelines for colorectal cancer screening 2009 [corrected]. Am J Gastroenterol. 2009;104:739–50. doi:10.1038/ajg.2009.104.
100. O’Connell JB, Maggard MA, Livingston EH, Yo CK. Colorectal cancer in the young. Am J Surg. 2004;187:343–8. doi:10.1016/j.amjsurg.2003.12.020.
101. Kim TJ, Kim ER, Hong SN, Chang DK, Kim Y-H. Long-term outcome and prognostic factors of sporadic colorectal cancer in young patients: a large institutional-based retrospective study. Medicine (Baltimore). 2016;95:e3641. doi:10.1097/MD.0000000000003641.
102. Scott RB, Rangel LE, Osler TM, Hyman NH. Rectal cancer in patients under the age of 50 years: the delayed diagnosis. Am J Surg. 2016;211:1014–8. doi:10.1016/j.amjsurg.2015.08.031.
103. Bleyer A, Barr R, Hayes-Lattin B, Thomas D, Ellis C, Anderson B, et al. The distinctive biology of cancer in adolescents and young adults. Nat Rev Cancer. 2008;8:288–98. doi:10.1038/nrc2349.
104. Stigliano V, Sanchez-Mete L, Martayan A, Anti M. Early-onset colorectal cancer: a sporadic or inherited disease? World J Gastroenterol. 2014;20:12420–30. doi:10.3748/wjg.v20.i35.12420.
105. de la Chapelle A. Microsatellite instability. N Engl J Med. 2003;349:209–10. doi:10.1056/NEJMp038099.
106. Sameer AS. Colorectal cancer: molecular mutations and polymorphisms. Front Oncol. 2013;3:114. doi:10.3389/fonc.2013.00114.
107. Armaghany T, Wilson JD, Chu Q, Mills G. Genetic alterations in colorectal cancer. Gastrointest Cancer Res. 2012;5:19–27. Available: http://www.ncbi.nlm.nih.gov/pubmed/22574233
108. Pino MS, Chung DC. The chromosomal instability pathway in colon cancer. Gastroenterology. 2010;138:2059–72. doi:10.1053/j.gastro.2009.12.065.
109. Sameer AS, Nissar S, Fatima K. Mismatch repair pathway: molecules, functions, and role in colorectal carcinogenesis. Eur J Cancer Prev. 2014;23:246–57. doi:10.1097/CEJ.0000000000000019.
110. Migliore L, Migheli F, Spisni R, Coppedè F. Genetics, cytogenetics, and epigenetics of colorectal cancer. J Biomed Biotechnol. 2011;2011:792362. doi:10.1155/2011/792362.
111. Chang DT, Pai RK, Rybicki LA, Dimaio MA, Limaye M, Jayachandran P, et al. Clinicopathologic and molecular features of sporadic early-onset colorectal adenocarcinoma: an adenocarcinoma with frequent signet ring cell differentiation, rectal and sigmoid involvement, and adverse morphologic features. Mod Pathol. 2012;25:1128–39. doi:10.1038/modpathol.2012.61.
112. Snover DC. Update on the serrated pathway to colorectal carcinoma. Hum Pathol. 2011;42:1–10. doi:10.1016/j.humpath.2010.06.002.
113. Raut CP, Pawlik TM, Rodriguez-Bigas MA. Clinicopathologic features in colorectal cancer patients with microsatellite instability. Mutat Res. 2004;568:275–82. doi:10.1016/j.mrfmmm.2004.05.025.
114. Cunningham D, Atkin W, Lenz H-J, Lynch HT, Minsky B, Nordlinger B, et al. Colorectal cancer. Lancet (London, England). 2010;375:1030–47. doi:10.1016/S0140-6736(10)60353-4.
115. Grady WM. Genomic instability and colon cancer. Cancer Metastasis Rev. 23:11–27. Available: http://www.ncbi.nlm.nih.gov/pubmed/15000146
116. Aaltonen LA, Peltomäki P, Leach FS, Sistonen P, Pylkkänen L, Mecklin JP, et al. Clues to the pathogenesis of familial colorectal cancer. Science. 1993;260:812–6. Available: http://www.ncbi.nlm.nih.gov/pubmed/8484121
117. Kovacs ME, Papp J, Szentirmay Z, Otto S, Olah E. Deletions removing the last exon of TACSTD1 constitute a distinct class of mutations predisposing to Lynch syndrome. Hum Mutat. 2009;30:197–203. doi:10.1002/humu.20942.
118. Kempers MJE, Kuiper RP, Ockeloen CW, Chappuis PO, Hutter P, Rahner N, et al. Risk of colorectal and endometrial cancers in EPCAM deletion-positive Lynch syndrome: a cohort study. Lancet Oncol. 2011;12:49–55. doi:10.1016/S1470-2045(10)70265-5.
119. Boland CR, Thibodeau SN, Hamilton SR, Sidransky D, Eshleman JR, Burt RW, et al. A National Cancer Institute Workshop on Microsatellite Instability for cancer detection and familial predisposition: development of international criteria for the determination of microsatellite instability in colorectal cancer. Cancer Res. 1998;58:5248–57. Available: http://www.ncbi.nlm.nih.gov/pubmed/9823339
120. Gryfe R, Kim H, Hsieh ET, Aronson MD, Holowaty EJ, Bull SB, et al. Tumor microsatellite instability and clinical outcome in young patients with colorectal cancer. N Engl J Med. 2000;342:69–77. doi:10.1056/NEJM200001133420201.
121. Losi L, Di Gregorio C, Pedroni M, Ponti G, Roncucci L, Scarselli A, et al. Molecular genetic alterations and clinical features in early-onset colorectal carcinomas and their role for the recognition of hereditary cancer syndromes. Am J Gastroenterol. 2005;100:2280–7. doi:10.1111/j.1572-0241.2005.00223.x.
122. Datta RV, LaQuaglia MP, Paty PB. Genetic and phenotypic correlates of colorectal cancer in young patients. N Engl J Med. 2000;342:137–8. doi:10.1056/NEJM200001133420216.
123. Durno C, Aronson M, Bapat B, Cohen Z, Gallinger S. Family history and molecular features of children, adolescents, and young adults with colorectal carcinoma. Gut. 2005;54:1146–50. doi:10.1136/gut.2005.066092.
124. Liu B, Farrington SM, Petersen GM, Hamilton SR, Parsons R, Papadopoulos N, et al. Genetic instability occurs in the majority of young patients with colorectal cancer. Nat Med. 1995;1:348–52. Available: http://www.ncbi.nlm.nih.gov/pubmed/7585065
125. Lukish JR, Muro K, DeNobile J, Katz R, Williams J, Cruess DF, et al. Prognostic significance of DNA replication errors in young patients with colorectal cancer. Ann Surg. 1998;227:51–6. Available: http://www.ncbi.nlm.nih.gov/pubmed/9445110
126. Pucciarelli S, Agostini M, Viel A, Bertorelle R, Russo V, Toppan P, et al. Early-age-at-onset colorectal cancer and microsatellite instability as markers of hereditary nonpolyposis colorectal cancer. Dis Colon rectum. 2003;46:305–12. doi:10.1097/01.DCR.0000054881.56204.F3.
127. Liang JT, Huang KC, Cheng AL, Jeng YM, Wu MS, Wang SM. Clinicopathological and molecular biological features of colorectal cancer in patients less than 40 years of age. Br J Surg. 2003;90:205–14. doi:10.1002/bjs.4015.
128. Popat S, Hubner R, Houlston RS. Systematic review of microsatellite instability and colorectal cancer prognosis. J Clin Oncol. 2005;23:609–18. doi:10.1200/JCO.2005.01.086.
129. Roth AD, Tejpar S, Delorenzi M, Yan P, Fiocca R, Klingbiel D, et al. Prognostic role of KRAS and BRAF in stage II and III resected colon cancer: results of the translational study on the PETACC-3, EORTC 40993, SAKK 60-00 trial. J Clin Oncol. 2010;28:466–74. doi:10.1200/JCO.2009.23.3452.
130. Hubbard J, Thomas DM, Yothers G, Green E, Blanke C, O’Connell MJ, et al. Benefits and adverse events in younger versus older patients receiving adjuvant chemotherapy for colon cancer: findings from the Adjuvant Colon Cancer Endpoints data set. J Clin Oncol. 2012;30:2334–9. doi:10.1200/JCO.2011.41.1975.
131. Perea J, Rueda D, Canal A, Rodríguez Y, Álvaro E, Osorio I, et al. Age at onset should be a major criterion for subclassification of colorectal cancer. J Mol Diagn. 2014;16:116–26. doi:10.1016/j.jmoldx.2013.07.010.
132. Silla IO, Rueda D, Rodríguez Y, García JL, de la Cruz VF, Perea J. Early-onset colorectal cancer: a separate subset of colorectal cancer. World J Gastroenterol. 2014;20:17288–96. doi:10.3748/wjg.v20.i46.17288.
133. Nazemalhosseini Mojarad E, Kuppen PJ, Aghdaei HA, Zali MR. The CpG island methylator phenotype (CIMP) in colorectal cancer. Gastroenterol Hepatol from bed to bench. 2013;6:120–8. Available: http://www.ncbi.nlm.nih.gov/pubmed/24834258
134. Hawkins NJ, Tomlinson I, Meagher A, Ward RL. Microsatellite-stable diploid carcinoma: a biologically distinct and aggressive subset of sporadic colorectal cancer. Br J Cancer. 2001;84:232–6. doi:10.1054/bjoc.2000.1554.
135. Chan TL, Curtis LC, Leung SY, Farrington SM, Ho JW, Chan AS, et al. Early-onset colorectal cancer with stable microsatellite DNA and near-diploid chromosomes. Oncogene. 2001;20:4871–6. doi:10.1038/sj.onc.1204653.
136. Banerjea A, Hands RE, Powar MP, Bustin SA, Dorudi S. Microsatellite and chromosomal stable colorectal cancers demonstrate poor immunogenicity and early disease recurrence. Color Dis. 2009;11:601–8. doi:10.1111/j.1463-1318.2008.01639.x.
137. Ogino S, Nosho K, Kirkner GJ, Kawasaki T, Chan AT, Schernhammer ES, et al. A cohort study of tumoral LINE-1 hypomethylation and prognosis in colon cancer. J Natl Cancer Inst. 2008;100:1734–8. doi:10.1093/jnci/djn359.
138. Cai G, Xu Y, Lu H, Shi Y, Lian P, Peng J, et al. Clinicopathologic and molecular features of sporadic microsatellite- and chromosomal-stable colorectal cancers. Int J Color Dis. 2008;23:365–73. doi:10.1007/s00384-007-0423-7.
139. Silver A, Sengupta N, Propper D, Wilson P, Hagemann T, Patel A, et al. A distinct DNA methylation profile associated with microsatellite and chromosomal stable sporadic colorectal cancers. Int J Cancer. 2012;130:1082–92. doi:10.1002/ijc.26104.
140. Antelo M, Balaguer F, Shia J, Shen Y, Hur K, Moreira L, et al. A high degree of LINE-1 hypomethylation is a unique feature of early-onset colorectal cancer. PLoS One. 2012;7:e45357. doi:10.1371/journal.pone.0045357.
141. Baba Y, Huttenhower C, Nosho K, Tanaka N, Shima K, Hazra A, et al. Epigenomic diversity of colorectal cancer indicated by LINE-1 methylation in a database of 869 tumors. Mol Cancer. 2010;9:125. doi:10.1186/1476-4598-9-125.
142. Stoffel EM, Kastrinos F. Familial colorectal cancer, beyond Lynch syndrome. Clin Gastroenterol Hepatol. 2014;12:1059–68. doi:10.1016/j.cgh.2013.08.015.
143. Nagase H, Nakamura Y. Mutations of the APC (adenomatous polyposis coli) gene. Hum Mutat. 1993;2:425–34. doi:10.1002/humu.1380020602.
144. Nieuwenhuis MH, Vasen HFA. Correlations between mutation site in APC and phenotype of familial adenomatous polyposis (FAP): a review of the literature. Crit Rev Oncol Hematol. 2007;61:153–61. doi:10.1016/j.critrevonc.2006.07.004.
145. Terdiman JP. MYH-associated disease: attenuated adenomatous polyposis of the colon is only part of the story. Gastroenterology. 2009;137:1883–6. doi:10.1053/j.gastro.2009.10.017.
146. Campos FG, Figueiredo MN, Martinez CAR. Colorectal cancer risk in hamartomatous polyposis syndromes. World J Gastrointest Surg. 2015;7:25–32. doi:10.4240/wjgs.v7.i3.25.
147. Chen H-M, Fang J-Y. Genetics of the hamartomatous polyposis syndromes: a molecular review. Int J Color Dis. 2009;24:865–74. doi:10.1007/s00384-009-0714-2.
148. Schreibman IR, Baker M, Amos C, McGarrity TJ. The hamartomatous polyposis syndromes: a clinical and molecular review. Am J Gastroenterol. 2005;100:476–90. doi:10.1111/j.1572-0241.2005.40237.x.
149. Zbuk KM, Eng C. Cancer phenomics: RET and PTEN as illustrative models. Nat Rev Cancer. 2007;7:35–45. doi:10.1038/nrc2037.
150. LaQuaglia MP, Heller G, Filippa DA, Karasakalides A, Vlamis V, Wollner N, et al. Prognostic factors and outcome in patients 21 years and under with colorectal carcinoma. J Pediatr Surg. 1992;27:1085–9. Available: http://www.ncbi.nlm.nih.gov/pubmed/1403541
151. Chiang J-M, Chen M-C, Changchien CR, Chen J-S, Tang R, Wang J-Y, et al. Favorable influence of age on tumor characteristics of sporadic colorectal adenocarcinoma: patients 30 years of age or younger may be a distinct patient group. Dis Colon rectum. 2003;46:904–10. doi:10.1097/01.DCR.0000075210.01797.11.
152. Tricoli JV, Seibel NL, Blair DG, Albritton K, Hayes-Lattin B. Unique characteristics of adolescent and young adult acute lymphoblastic leukemia, breast cancer, and colon cancer. J Natl Cancer Inst. 2011;103:628–35. doi:10.1093/jnci/djr094.
153. Hill DA, Furman WL, Billups CA, Riedley SE, Cain AM, Rao BN, et al. Colorectal carcinoma in childhood and adolescence: a clinicopathologic review. J Clin Oncol. 2007;25:5808–14. doi:10.1200/JCO.2007.12.6102.
154. Sargent DJ, Marsoni S, Monges G, Thibodeau SN, Labianca R, Hamilton SR, et al. Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer. J Clin Oncol. 2010;28:3219–26. doi:10.1200/JCO.2009.27.1825.
155. National Comprehensive Cancer Network. NCCN guidelines—colon cancer [Internet]. Available: https://www.nccn.org/professionals/physician_gls/pdf/colon.pdf.
156. • Ben-Aharon R, Pelossof R, Elkabets M. Early-onset colorectal cancer—does the difference lie in epigenetics? Eur Cancer Congr. 2015:Abstract 2189. doi:10.1016/S0959-8049(16)31108-X. This exploratory study investigated differences between somatic gene expression in cohorts of patients younger and older than age 50 years
157. Kirzin S, Marisa L, Guimbaud R, De Reynies A, Legrain M, Laurent-Puig P, et al. Sporadic early-onset colorectal cancer is a specific sub-type of cancer: a morphological, molecular and genetics study. PLoS One. 2014;9:e103159. doi:10.1371/journal.pone.0103159.
158. Surveillance, Epidemiology, and End Results (SEER) Program (www.seer.cancer.gov) SEER*Stat database: incidence—SEER 9 Regs Research Data, Nov 2015 Sub (1973–2013)−Linked To County Attributes - Total U.S., 1969–2014 Counties, National Cancer Institute, DCCPS, Surveillance Research Program, Surveillance Systems Branch, released April 2016, based on the November 2015 submission.